Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinquair in eosinophilic asthma
NCT01287039Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of reslizumab in eosinophilic asthma (EA), sponsored by Teva Pharmaceutical Industries Ltd.. Started Apr 2011; status: completed.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT01287039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287039.